Five Prime Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 61.47 | -100% | -2.53 | -100% |
| P/S |
|
106.2 | 33.58 | 216.26% |
|
|
| P/BV |
|
6.7 | 4.79 | 39.81% |
|
|
| P/FCF |
|
-27.23 | 60.06 | -145.34% |
|
|
| Ev/Ebitda |
|
-20.45 | -17.26 | 18.48% |
|
|
| Ev/S |
|
115.38 | 22.5 | 412.76% |
|
|
| Ev/FCF |
|
-23.08 | 69 | -133.44% |
|
|
| E/P |
|
-0.0475 | 0.0168 | -382.03% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.5 | -100% | -379.2 | -100% |
| ROE |
|
-40.58 | 9.39 | -532.1% |
|
|
| ROA |
|
-30.35 | 0.1519 | -20077.03% |
|
|
| ROIC |
|
-32.9 | 7.63 | -530.95% |
|
|
| ROS |
|
-646.15 | -25.64 | 2420.02% |
|
|
| ROCE |
|
0 | 15.19 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.6475 | -3.67 | -82.34% | -0.6475 | 0% |
| Nеt Debt/Ebitda |
|
0 | -4.06 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.199 | -100% |
|
|
| Debt/Equity |
|
0 | 1.54 | -100% |
|
|
| Debt/Net Income |
|
-0.5643 | 10.34 | -105.46% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2331 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4916 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.32 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-58.06 | 76.2 | -176.19% | ||
| Growth impulse Ebitda in 5 years |
|
-17.92 | 44.75 | -140.04% | ||
| Growth impulse Net Income in 5 years |
|
27.27 | -15.36 | -277.54% | ||
| Growth impulse FCF in 5 years |
|
-21.69 | -9.39 | 130.99% | ||
| Growth impulse EPS in 5 years |
|
-6.15 | -84.03 | -92.68% |
IP Score
2.51/10
